WO2011160096A3 - Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition - Google Patents

Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition Download PDF

Info

Publication number
WO2011160096A3
WO2011160096A3 PCT/US2011/040998 US2011040998W WO2011160096A3 WO 2011160096 A3 WO2011160096 A3 WO 2011160096A3 US 2011040998 W US2011040998 W US 2011040998W WO 2011160096 A3 WO2011160096 A3 WO 2011160096A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoantibodies
biomarkers
condition
autoantigens
neurological disorder
Prior art date
Application number
PCT/US2011/040998
Other languages
French (fr)
Other versions
WO2011160096A2 (en
Inventor
Kevin Ka-Wang Wang
Zhiqun Zhang
Original Assignee
Banyan Biomarkers, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyan Biomarkers, Inc. filed Critical Banyan Biomarkers, Inc.
Publication of WO2011160096A2 publication Critical patent/WO2011160096A2/en
Publication of WO2011160096A3 publication Critical patent/WO2011160096A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of one or more autoantibodies to biomarkers in a biological fluid such as CSF or serum for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.
PCT/US2011/040998 2010-06-17 2011-06-17 Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition WO2011160096A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35577910P 2010-06-17 2010-06-17
US61/355,779 2010-06-17
US201161476158P 2011-04-15 2011-04-15
US61/476,158 2011-04-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/048789 Continuation-In-Part WO2011032155A2 (en) 2009-09-14 2010-09-14 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
US13/395,931 Continuation-In-Part US20130022982A1 (en) 2009-09-14 2010-09-14 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Publications (2)

Publication Number Publication Date
WO2011160096A2 WO2011160096A2 (en) 2011-12-22
WO2011160096A3 true WO2011160096A3 (en) 2012-04-26

Family

ID=45348920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/040998 WO2011160096A2 (en) 2010-06-17 2011-06-17 Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition

Country Status (1)

Country Link
WO (1) WO2011160096A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2733990C (en) 2008-08-11 2018-12-11 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20130022982A1 (en) 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
EP3509646A4 (en) 2016-09-09 2020-06-17 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating autoimmune gfap astrocytopathy
CN109790584A (en) 2016-09-27 2019-05-21 梅奥医学教育及研究基金会 For evaluating and the material and method for the treatment of cancer
WO2018132639A1 (en) * 2017-01-13 2018-07-19 Foster Charles Stephen Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid
US10345302B2 (en) * 2017-02-19 2019-07-09 Sheng-He Huang Circulating astrocytes and MFSD2A as biomarkers
JP7346300B2 (en) 2017-03-23 2023-09-19 アボット・ラボラトリーズ Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in human subjects using the early biomarker ubiquitin carboxy-terminal hydrolase L1
AU2018250688A1 (en) 2017-04-15 2019-08-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018200823A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
AU2018272054A1 (en) 2017-05-25 2019-09-26 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
CN110709704A (en) 2017-05-30 2020-01-17 雅培实验室 Method for auxiliary diagnosis and evaluation of mild traumatic brain injury of human subjects by using cardiac troponin I
JP7454945B2 (en) 2017-07-03 2024-03-25 アボット・ラボラトリーズ Improved method for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
CN107629112B (en) * 2017-09-07 2020-10-27 北京大学 High-affinity LC3 protein targeting peptide and application thereof
BR112020010085A2 (en) 2017-12-09 2020-10-13 Abbott Laboratories methods to assist in the diagnosis and assessment of a traumatic brain injury in a human subject using a combination of gfap and uch-l1
JP7344801B2 (en) 2017-12-09 2023-09-14 アボット・ラボラトリーズ Glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) Methods to assist in diagnosis and assessment of injuries sustained or potential injuries
JP7437303B2 (en) 2017-12-29 2024-02-22 アボット・ラボラトリーズ Novel biomarkers and methods for diagnosing and assessing traumatic brain injury
CN112175079A (en) * 2020-10-10 2021-01-05 武汉华美生物工程有限公司 Preparation method and application of multifunctional anti-GFAP monoclonal antibody
CN112505329A (en) * 2020-10-20 2021-03-16 山东第一医科大学(山东省医学科学院) Application of mGluR1a breakage and early warning detection reagent for late-onset cerebral ischemia after subarachnoid hemorrhage
JP2023551542A (en) 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド Non-invasive assessment of Alzheimer's disease
US20220308053A1 (en) * 2021-03-29 2022-09-29 Euroimmun Medizinische Labordiagnostika Ag Method and reagents for the detection of an autoantibody
CN113238045B (en) * 2021-04-27 2021-12-28 南方医科大学南方医院 Applications of CRMP2 and anti-CRMP 2 antibody
CN113671179B (en) * 2021-09-02 2023-10-03 中国科学院深圳先进技术研究院 Kit for detecting KCNAB2 autoantibody as well as detection method and application thereof
WO2024107948A1 (en) * 2022-11-16 2024-05-23 Gryphon Bio, Inc. Biomarker panel for brain specific abnormal neurological conditions using biofluid samples

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20050260697A1 (en) * 2004-04-15 2005-11-24 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
US20050260654A1 (en) * 2004-04-15 2005-11-24 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2010019553A2 (en) * 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20050260697A1 (en) * 2004-04-15 2005-11-24 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
US20050260654A1 (en) * 2004-04-15 2005-11-24 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
WO2010019553A2 (en) * 2008-08-11 2010-02-18 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition

Also Published As

Publication number Publication date
WO2011160096A2 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
WO2011160096A3 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
WO2010019553A3 (en) Biomarker detection process and assay of neurological condition
WO2011032155A3 (en) Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
WO2010148391A3 (en) Biomarker assay of neurological condition
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
WO2012054589A3 (en) Conduit-containing devices and methods for analyte processing and detection
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
WO2012004790A3 (en) Nucleic acid aptamer-based detection methods characterized by signal enhancement
EP2569635A4 (en) Methods for diagnosing and treating encephalitis or epilepsy
EP3757226A3 (en) A multi-protein biomarker assay for brain injury detection and outcome
BRPI1007321A2 (en) methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
WO2013009703A3 (en) Antibodies, kit and method for detecting amyloid beta oligomers
BR112014032304A2 (en) sandwich method, system and assay for the quantitative or qualitative determination of a target component in a liquid sample, kit for preparing a liquid sample, and microfluidic device.
WO2016205637A3 (en) Detection of cerebrospinal fluid
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
WO2013128500A9 (en) Die-cast product strength evaluation method and die-cast product
BR112014000219A2 (en) Assay device for detecting an active enzyme in a sample, method for determining the presence and levels of an active enzyme in a sample, kit, assay device, or method of use or use and use
WO2016205828A3 (en) Role of citrullination in diagnosing diseases
WO2013167727A3 (en) Method for determining arthritis relapse risk
SG10201806729VA (en) Novel assay to detect human periostin
WO2013064702A3 (en) Probes for diagnosis and monitoring of neurodegenerative disease
GB201119585D0 (en) Assay
WO2011113813A3 (en) Assay for analytes based on aggregation
WO2011150509A3 (en) Diagnosing asthma based on pentraxin-3
WO2011052906A3 (en) Use of eif3m for the diagnosis and treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11796565

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11796565

Country of ref document: EP

Kind code of ref document: A2